Can a smart oxygen device shorten hospital stays for pneumonia?

NCT ID NCT03527992

Completed Disease control Sponsor: University Hospital, Toulouse Source: ClinicalTrials.gov ↗

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial tests whether an automated oxygen delivery system, called FreeO2, can help patients with pneumonia recover faster and leave the hospital sooner. The device automatically adjusts oxygen flow based on continuous monitoring of blood oxygen levels, aiming to keep patients in a target range. Researchers compare this to standard oxygen therapy in adults hospitalized with pneumonia and low oxygen levels. The main goal is to see if automated oxygen reduces the total length of hospital stay.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Automated oxygen delivery via the FreeO2 device, which adjusts oxygen flow based on continuous saturation monitoring
What this could lead to: If effective, this automated system could reduce hospital stays for pneumonia patients, freeing up beds and lowering healthcare costs.
What could go wrong: The trial is small and early, and results may not apply to all pneumonia patients. The device might not significantly shorten hospital stays or could have technical issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LENGTH OF STAY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumonia Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LENGTH OF STAY PNEUMONIA PNEUMONIA, VENTILATOR-ASSOCIATED

Contacts and locations

Locations

CHU Larrey

Toulouse, 31049, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.